GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » Cyclically Adjusted Price-to-FCF

Evoke Pharma (STU:EV00) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evoke Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Evoke Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Cyclically Adjusted Price-to-FCF Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evoke Pharma's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Cyclically Adjusted Price-to-FCF falls into.



Evoke Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Evoke Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Evoke Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.303/129.4194*129.4194
=-0.303

Current CPI (Dec. 2023) = 129.4194.

Evoke Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2.894 99.695 -3.757
201406 -4.498 100.560 -5.789
201409 -6.012 100.428 -7.748
201412 -4.058 99.070 -5.301
201503 -5.436 99.621 -7.062
201506 -4.376 100.684 -5.625
201509 -4.124 100.392 -5.316
201512 -3.790 99.792 -4.915
201603 -4.047 100.470 -5.213
201606 -3.303 101.688 -4.204
201609 -2.434 101.861 -3.093
201612 -1.265 101.863 -1.607
201703 -1.399 102.862 -1.760
201706 -1.451 103.349 -1.817
201709 -1.443 104.136 -1.793
201712 -1.788 104.011 -2.225
201803 -1.777 105.290 -2.184
201806 -1.102 106.317 -1.341
201809 -0.691 106.507 -0.840
201812 -0.756 105.998 -0.923
201903 -1.170 107.251 -1.412
201906 -0.744 108.070 -0.891
201909 -0.478 108.329 -0.571
201912 -0.510 108.420 -0.609
202003 -0.690 108.902 -0.820
202006 -0.664 108.767 -0.790
202009 -0.706 109.815 -0.832
202012 -0.640 109.897 -0.754
202103 -0.956 111.754 -1.107
202106 -0.464 114.631 -0.524
202109 -1.847 115.734 -2.065
202112 -0.649 117.630 -0.714
202203 -0.537 121.301 -0.573
202206 -0.412 125.017 -0.427
202209 -0.333 125.227 -0.344
202212 -0.708 125.222 -0.732
202303 -0.456 127.348 -0.463
202306 -0.333 128.729 -0.335
202309 -0.292 129.860 -0.291
202312 -0.303 129.419 -0.303

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evoke Pharma  (STU:EV00) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Evoke Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (STU:EV00) Business Description

Industry
Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines